Trials / Completed
CompletedNCT00664599
Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Tehran University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.
Detailed description
To test in a single blind randomized control study the efficacy of Rituximab versus combination of pulse cyclophosphamide and azathioprine. Both group receiving 0.5 mg/kg/daily prednisolone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily). |
| DRUG | Cytotoxic Combination | Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily. |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2008-04-23
- Last updated
- 2008-04-30
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT00664599. Inclusion in this directory is not an endorsement.